AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02110940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization exercise
Description: The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.~Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise.
Study NCT02110940 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Physiotherapy
Description: The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
Study NCT03901053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reaktiv AFO
Description: This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.
Study NCT03901053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PhatBrace AFO
Description: Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.
Study NCT03466125 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Retrospective cohort study
Study NCT03802565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone
Description: TID
Study NCT03802565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06244498 — intervention group
Intervention type: DRUG
Intervention: Tranexamic acid injection
Description: Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery.
Study NCT02277158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: S-1 CCRT
Study NCT03925584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Standardized music playlist will be played centrally at the subjects head or feet for a period of 20 minutes once during a 12-hour shift for 14 days or until mechanical ventilation has been discontinued, whichever is first
Study NCT02664922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures.
Study NCT02664922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures.
Study NCT02664922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
Study NCT02664922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1 general anesthesia group for VT ablations and afib procedures.
Study NCT02806544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 20mg by mouth daily
Study NCT00073892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: 250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle
Study NCT01334580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Pain and Opioid Dependence
Description: CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
Study NCT01334580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Methadone Drug Counseling
Description: Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.
Study NCT02149316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC+RIPostC
Description: Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
Study NCT01451697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: A computerized cognitive remediation program focused on attentional training will be used.
Study NCT02149316 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control
Description: a deflated cuff placed on the right upper arm
Study NCT03160222 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Body Composition Measurements
Description: Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
Study NCT01157000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: On Day 1, all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
Study NCT00759057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior Pedicle Screw System
Description: Implantation of Posterior Pedicle Screw System
Study NCT00759057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Pedicle Screw System
Description: Implantation of Posterior Pedicle Screw System
Study NCT01893580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: 1. Experimental
Description: Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~1. Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~2. Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM.
Study NCT01893580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: 2. Experimental
Description: Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:~1. Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~2. Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM.
Study NCT01893580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: 3. Experimental
Description: Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM.
Study NCT01893580 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Other: 4. Usual care
Description: Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.~The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM.
Study NCT04003545 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LED Photobiomodulation
Description: A total of twelve laser applications (3 sessions per week) will be provided to the patients as treatment. A LED board with wavelengths of 660nm and 850nm at 5mW of power will be used for 30 minutes, resulting in a total energy of 3J per point in each session. The application site will be the lumbar region, in contact with the skin. The LED cluster (light-emitting diodes) has 72 LEDs.
Study NCT04003545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LED Photobiomodulation
Description: For the placebo group, the procedures will be the same, however the LED equipment will remain off.
Study NCT01319240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
Study NCT01319240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
Study NCT01319240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
Study NCT03605940 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methoxsalen + ECP device
Description: 2 sessions per week during 4 weeks and 1 session per week during 8 weeks
Study NCT03605940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: 2 mg/kg/day
Study NCT03605940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: 2 mg/kg/day
Study NCT01523015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative chemo- and chemoradiotherapy
Description: 2 cycles of triple regimen chemotherapy consisting of docetaxel (75mg/m2 iv infusion), oxaliplatin (130mg/m2 iv infusion) and 5-fluorouracil (750mg/m2 iv infusion followed by fractionated irradiation (total dose 45Gy in 25 fractions of 1,8Gy) combined with chemotherapy consisting of 3 cycles of 1-day chemotherapy with docetaxel (50mg/m2 iv infusion) and oxaliplatin (85mg/m2 iv infusion
Study NCT01523015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection
Description: The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
Study NCT00642109 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: midurethral sling procedure
Description: quality of life, voiding dysfunction
Study NCT04197895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation with APRF
Description: Socket preservation with APRF , A-PRF membranes were implanted into the extraction socket following tooth extraction. One entire A-PRF membrane would be placed at the base of the extraction socket and another A-PRF membrane will cover the extraction site then suturing will be done .Venous blood will be collected via venipuncture of the forearm with a butterfly needle into at least 10 mL sterile glass vacuum tube. The blood sample will be immediately centrifuged at 1,300 rpm (200 x g) for 8 minutes
Study NCT04197895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: natural healing
Description: after atraumatic extraction , the socket will be left for natural healing after suturing
Study NCT00615979 — intervention group
Intervention type: DEVICE
Intervention: Miniature echo machine
Description: Images captured and real-time and store-and-forward file transfers performed
Study NCT02595281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Serum samples are collected:~* at each neoadjuvant chemotherapy cycle~* before surgery~* at each adjuvant chemotherapy cycle~* at each injection of bevacizumab as maintenance therapy~* stop at the progression or after 24 months post chemotherapy
Study NCT00081731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atacand/HCT, Caduet
Description: Atacand/HCT and caduet or optimal medical therapy for hypertension
Study NCT00081731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)
Description: Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
Study NCT03229148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: Procedure in which patients are induced into an unconscious state through use of various medications so that they do not feel pain during surgery
Study NCT03229148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conscious Sedation
Description: A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines)
Study NCT00757185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganirelix acetate
Description: GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
Study NCT00757185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl testosterone
Description: testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
Study NCT01617772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20 mg
Study NCT01617772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: 1000mg L-carnitine
Study NCT01617772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically looking placebo
Study NCT00785213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone 4 mg Tablets
Description: Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.
Study NCT00785213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg Tablets
Description: Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
Study NCT00785213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate 324 mg Capsules
Description: Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
Study NCT01917305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: platform-shifted implant
Study NCT01917305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: platform-shifted implant
Study NCT03871816 — intervention group
Intervention type: OTHER
Intervention: Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis
Description: Saliva, blood, and/or archival tumor tissue will be collected from the participants with metastatic PC for genomic testing to confirm DRD status.
Study NCT01071239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACs device
Description: Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device
Study NCT01071239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Chemotherapy administered as a part of the HSCT conditioning regimen.
Study NCT01071239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy administered as a part of the HSCT conditioning regimen.
Study NCT01071239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy administered as a part of the HSCT conditioning regimen.
Study NCT01071239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: Chemotherapy administered as a part of the HSCT conditioning regimen.
Study NCT04469673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological：JS002
Description: Administered by subcutaneous injection
Study NCT04469673 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT01860742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon alpha-2b
Description: Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day
Study NCT01860742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTATATE
Description: 177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution
Study NCT01902875 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel + Cisplatin
Description: Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.
Study NCT01902875 — intervention group
Intervention type: BIOLOGICAL
Intervention: CIK cell therapy
Description: Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).
Study NCT03840148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime/VNRX-5133 (taniborbactam)
Description: Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.
Study NCT03840148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.
Study NCT00919906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: My Scrivener(R)
Description: Twenty 20-minute sessions of the Handwriting Without Tears(R) instructional handwriting program, with substitution of hand-over-hand or self-generated repetitive motion writing by computer guided repetitive motion.
Study NCT03098056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROG2
Description: Nutritional Supplements to be administered:~* Protein Shakes: one shake po twice daily~* Phytosterol supplement: one capsule po twice daily~* Cinnamon: one tablet twice daily~* Fiber supplement; one shake twice daily~* Antioxidant supplement: 2 capsules daily with dinner~* Fish Oil supplement: 1 capsule twice daily with food~* Probiotic supplement: 1 capsule twice daily with food
Study NCT00691873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00691873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
Study NCT03488849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SureCRIC
Description: SureCRIC is intended to be used as an accessory to cricothyrotomy and tracheotomy devices, helping to identify and stabilize anatomical landmarks for establishing an airway.
Study NCT03488849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Freehand
Description: Freehand palpation approach to identification of the cricothyroid membrane
Study NCT01152216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: 20 mg orally three times daily
Study NCT02690519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 dose 1
Description: one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
Study NCT02690519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 dose 2
Description: one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks